HomeCompareJCRRF vs KO

JCRRF vs KO: Dividend Comparison 2026

JCRRF yields 3.22% · KO yields 2.70%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JCRRF wins by $590.29M in total portfolio value
10 years
JCRRF
JCRRF
● Live price
3.22%
Share price
$4.17
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$590.33M
Annual income
$557,098,169.44
Full JCRRF calculator →
KO
The Coca-Cola Company
● Live price
2.70%
Share price
$76.27
Annual div
$2.06
5Y div CAGR
24.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.1K
Annual income
$4,303.79
Full KO calculator →

Portfolio growth — JCRRF vs KO

📍 JCRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCRRFKO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCRRF + KO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JCRRF pays
KO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCRRF
Annual income on $10K today (after 15% tax)
$273.77/yr
After 10yr DRIP, annual income (after tax)
$473,533,444.02/yr
KO
Annual income on $10K today (after 15% tax)
$229.58/yr
After 10yr DRIP, annual income (after tax)
$3,658.22/yr
At 15% tax rate, JCRRF beats the other by $473,529,785.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCRRF + KO for your $10,000?

JCRRF: 50%KO: 50%
100% KO50/50100% JCRRF
Portfolio after 10yr
$295.18M
Annual income
$278,551,236.61/yr
Blended yield
94.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KO right now

JCRRF
No analyst data
Altman Z
1.4
Piotroski
4/9
KO
Analyst Ratings
29
Buy
16
Hold
3
Sell
Consensus: Buy
Price Target
$84.88
+11.3% upside vs current
Range: $81.00 — $88.00
Altman Z
5.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCRRF buys
0
KO buys
0
No recent congressional trades found for JCRRF or KO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCRRFKO
Forward yield3.22%2.70%
Annual dividend / share$0.13$2.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%24.3%
Portfolio after 10y$590.33M$34.1K
Annual income after 10y$557,098,169.44$4,303.79
Total dividends collected$587.89M$15.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: JCRRF vs KO ($10,000, DRIP)

YearJCRRF PortfolioJCRRF Income/yrKO PortfolioKO Income/yrGap
1← crossover$11,344$644.17$10,846$335.73+$498.00JCRRF
2$13,504$1,365.91$11,829$430.64+$1.7KJCRRF
3$17,489$3,039.22$12,988$555.50+$4.5KJCRRF
4$26,070$7,356.96$14,372$721.34+$11.7KJCRRF
5$48,393$20,498.67$16,049$944.01+$32.3KJCRRF
6$122,906$71,124.57$18,114$1,246.74+$104.8KJCRRF
7$469,147$337,637.75$20,702$1,664.24+$448.4KJCRRF
8$2,910,974$2,408,986.96$24,008$2,249.48+$2.89MJCRRF
9$31,053,709$27,938,966.99$28,317$3,085.19+$31.03MJCRRF
10$590,325,638$557,098,169.44$34,065$4,303.79+$590.29MJCRRF

JCRRF vs KO: Complete Analysis 2026

JCRRFStock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Full JCRRF Calculator →

KOConsumer Staples

The Coca-Cola Company, a beverage company, manufactures, markets, and sells various nonalcoholic beverages worldwide. The company provides sparkling soft drinks, sparkling flavors; water, sports, coffee, and tea; juice, value-added dairy, and plant-based beverages; and other beverages. It also offers beverage concentrates and syrups, as well as fountain syrups to fountain retailers, such as restaurants and convenience stores. The company sells its products under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero Sugar, caffeine free Diet Coke, Cherry Coke, Fanta Orange, Fanta Zero Orange, Fanta Zero Sugar, Fanta Apple, Sprite, Sprite Zero Sugar, Simply Orange, Simply Apple, Simply Grapefruit, Fresca, Schweppes, Thums Up, Aquarius, Ayataka, BODYARMOR, Ciel, Costa, Dasani, dogadan, FUZE TEA, Georgia, glacéau smartwater, glacéau vitaminwater, Gold Peak, Ice Dew, I LOHAS, Powerade, Topo Chico, AdeS, Del Valle, fairlife, innocent, Minute Maid, and Minute Maid Pulpy brands. It operates through a network of independent bottling partners, distributors, wholesalers, and retailers, as well as through bottling and distribution operators. The company was founded in 1886 and is headquartered in Atlanta, Georgia.

Full KO Calculator →
📬

Get this JCRRF vs KO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCRRF vs SCHDJCRRF vs JEPIJCRRF vs OJCRRF vs MAINJCRRF vs PEPJCRRF vs PGJCRRF vs JNJJCRRF vs MCD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.